In July 2016 BMC supported OncoArendi Therapeutics in grant application for the project “Development of a first-in-class small molecule drug candidate for cancer treatment through YKL 40 inhibition” in the 1/1.1.1/2016 (“Fast track”) program by The National Centre for Research and Development. The project included substantive preparation of the grant application parts, concerning: – market… Read more »